Dr Richard Weaver
Senior Vice President - Pre-Clinical Development
Richard joined Sygnature in 2020 to head up a newly established function focused on pre-clinical development with the creation of the Form & Formulation department.
With a clear focus on influencing and enhancing the success rate of pre-clinical candidates in order to maximise the success of launching needed new drugs, Richard has been instrumental in bringing formulation into the integrated offering at Sygnature, giving clients a seamless approach from early-stage discovery into early development and the clinic.
Prior to joining Sygnature, Richard founded XenoGesis in 2011. His clear scientific rationale, business direction, vision and entrepreneurial approach was behind XenoGesis’ consistent expansion and growth which resulted in the creation of the UK’s largest independent DMPK contract research organisation. XenoGesis won multiple awards, including the Queen’s Award for Enterprise, built a client base over 200 companies and universities across the globe, and provided experimental data, advice, and PK predictions on multiple projects, including nine compounds that are now in the clinic.
Richard gained a first-class honours degree in chemistry with awards for the best performance in every year, followed by a medicinal chemistry PhD with a Wellcome Trust scholarship at the University of Leicester and two subsequent postdoctoral positions at the Welsh School of Pharmacy. In 1997, Richard joined Astra Charnwood within Discovery DMPK, and progressed to Group and Project Leader at AstraZeneca. During that time Richard gained and developed an in-depth knowledge of all aspects of in vitro and in vivo DMPK from hit identification to candidate drug nomination and beyond.
In 2014, Richard was invited to become a Fellow of the Royal Society of Chemistry. Richard has also authored and co-authored twenty-one publications to date.
- Bridging The Gap Between Discovery and Development – DMPK Influence
6 October 2021 9:35 am